BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22785086)

  • 1. Changing illness perceptions and adherence to dual antiplatelet therapy in patients with stable coronary disease.
    Fennessy MM; Devon HA; Ryan C; Lopez JJ; Zerwic JJ
    J Cardiovasc Nurs; 2013; 28(6):573-83. PubMed ID: 22785086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual antiplatelet therapy in patients with stable coronary artery disease in modern practice: prevalence, correlates, and impact on prognosis (from the Suivi d'une cohorte de patients COROnariens stables en region NORd-Pas-de-Calais study).
    Lemesle G; Lamblin N; Meurice T; Tricot O; Lallemant R; Nugue O; Delomez M; Equine O; Tondeux S; Bauters C
    Am Heart J; 2014 Oct; 168(4):479-86. PubMed ID: 25262257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial.
    Dangas GD; Claessen BE; Mehran R; Xu K; Stone GW
    EuroIntervention; 2013 Jan; 8(9):1033-9. PubMed ID: 23339809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percutaneous coronary intervention vs. optimal medical therapy--the other side of the coin: medication adherence.
    Kocas C; Abaci O; Oktay V; Coskun U; Bostan C; Yildiz A; Arat Ozkan A; Gurmen T; Ersanli M
    J Clin Pharm Ther; 2013 Dec; 38(6):476-9. PubMed ID: 23992279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.
    Resor CD; Nathan A; Kereiakes DJ; Yeh RW; Massaro JM; Cutlip DE; Gabriel Steg P; Hsieh WH; Mauri L;
    Circulation; 2016 Oct; 134(14):989-998. PubMed ID: 27576774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet effect of aspirin in patients with coronary artery disease.
    Grove EL
    Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
    Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
    Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telephone contact to improve adherence to dual antiplatelet therapy after drug-eluting stent implantation.
    Rinfret S; Rodés-Cabau J; Bagur R; Déry JP; Dorais M; Larose E; Barbeau G; Gleeton O; Nguyen CM; Noël B; Proulx G; Roy L; Taillon I; De Larochellière R; Bertrand OF;
    Heart; 2013 Apr; 99(8):562-9. PubMed ID: 23434769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry).
    Schoos M; Chandrasekhar J; Baber U; Bhasin A; Sartori S; Aquino M; Vogel B; Farhan S; Sorrentino S; Kini A; Kruckoff M; Moliterno D; Henry TD; Weisz G; Gibson CM; Iakovou I; Colombo A; Steg PG; Witzenbichler B; Chieffo A; Cohen D; Stuckey T; Ariti C; Dangas G; Pocock S; Mehran R
    Am J Cardiol; 2017 Sep; 120(6):904-910. PubMed ID: 28778417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to antiplatelet therapy after percutaneous coronary intervention: a population study in a region of Italy.
    Pinnarelli L; Mayer F; Bauleo L; Agabiti N; Kirchmayer U; Belleudi V; Di Martino M; Autore C; Ricci R; Violini R; Fusco D; Davoli M; Perucci CA
    J Cardiovasc Med (Hagerstown); 2015 Mar; 16(3):230-7. PubMed ID: 25325532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet therapy for improving post-PCI outcomes: interpreting current treatment guidelines for optimal management of the post-ACS patient.
    Cross J
    Am J Manag Care; 2009 Mar; 15(2 Suppl):S48-53. PubMed ID: 19355809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease.
    Larsen SB; Grove EL; Kristensen SD; Hvas AM
    Thromb Haemost; 2013 May; 109(5):920-9. PubMed ID: 23407706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
    Tada T; Natsuaki M; Morimoto T; Furukawa Y; Nakagawa Y; Byrne RA; Kastrati A; Kadota K; Iwabuchi M; Shizuta S; Tazaki J; Shiomi H; Abe M; Ehara N; Mizoguchi T; Mitsuoka H; Inada T; Araki M; Kaburagi S; Taniguchi R; Eizawa H; Nakano A; Suwa S; Takizawa A; Nohara R; Fujiwara H; Mitsudo K; Nobuyoshi M; Kita T; Kimura T;
    Circ Cardiovasc Interv; 2012 Jun; 5(3):381-91. PubMed ID: 22619260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.
    Valgimigli M; Campo G; de Cesare N; Meliga E; Vranckx P; Furgieri A; Angiolillo DJ; Sabatè M; Hamon M; Repetto A; Colangelo S; Brugaletta S; Parrinello G; Percoco G; Ferrari R;
    Circulation; 2009 Jun; 119(25):3215-22. PubMed ID: 19528337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).
    Campo G; Tebaldi M; Vranckx P; Biscaglia S; Tumscitz C; Ferrari R; Valgimigli M
    J Am Coll Cardiol; 2014 Feb; 63(6):506-12. PubMed ID: 24161321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-adherence to aspirin in patients undergoing coronary stenting: negative impact of comorbid conditions and implications for clinical management.
    Cuisset T; Quilici J; Fugon L; Cohen W; Roux P; Gaborit B; Molines L; Fourcade L; Bonnet JL; Carrieri P
    Arch Cardiovasc Dis; 2011 May; 104(5):306-12. PubMed ID: 21693367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT; Regal RE; Dorsch MP
    Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease.
    Würtz M; Grove EL; Kristensen SD; Hvas AM
    Heart; 2010 Mar; 96(5):368-71. PubMed ID: 19910291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
    Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM
    Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention.
    Borden WB; Redberg RF; Mushlin AI; Dai D; Kaltenbach LA; Spertus JA
    JAMA; 2011 May; 305(18):1882-9. PubMed ID: 21558519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.